填补国内空白！万华化学供应商，巨化旗下化工新材料龙头上市

Core Viewpoint - Jinhua New Materials is set to be listed on the Beijing Stock Exchange with an IPO price of 18.15 CNY per share, aiming to raise 63.105 million CNY for various projects, including a high-end coupling agent project that will significantly increase production capacity [2][4]. Project Summaries - The IPO will raise funds for three main projects: - 60kt/a high-end coupling agent project with an investment of 50689.75 thousand CNY, which will add 30,000 tons/year of silane coupling agent capacity and 30,000 tons/year of functional silane intermediate capacity [2][3]. - 500 tons/year JH-2 pilot project with an investment of 3058.18 thousand CNY, aimed at developing hydroxylamine aqueous solution for use in chip manufacturing and special fiber production [2][3]. - Ketoxime industry chain smart factory construction project with an investment of 6310.50 thousand CNY [2][3]. Company Overview - Jinhua New Materials, established in December 2007, is a leading domestic enterprise in silane crosslinking agents and hydroxylamine salts, recognized as a national-level "little giant" enterprise [4]. - The company is state-owned, with the chemical giant Juhua Group as the largest shareholder, holding 82.49% of the shares [4]. - Major clients include Bayer, Bruntag, and several listed companies such as Wanhua Chemical and Xin'an Chemical [4]. Financial Performance - Projected revenues for Jinhua New Materials from 2022 to 2025 are as follows: - 2022: 994 million CNY - 2023: 1.115 billion CNY - 2024: 1.239 billion CNY - 2025: 1.063 billion CNY (a decrease of 14.25% year-on-year) [4]. - Net profits for the same period are projected as: - 2022: 79.592 million CNY - 2023: 173 million CNY - 2024: 211 million CNY - 2025: 199 million CNY (a decrease of 5.47% year-on-year) [4]. Market Position - Silane crosslinking agents are expected to generate 714 million CNY in revenue in 2024, accounting for 57.9% of total revenue, with a domestic market share of 38.16% [5]. - Hydroxylamine salts are projected to bring in 368 million CNY in revenue in 2024, representing 30% of total revenue, with a domestic market share of 42.37% [5]. - The company has a competitive position in the hydroxylamine salt market, with significant production capacity compared to other domestic players [5].